Table 1.
Clinical features.
| Feature | Value |
|---|---|
| SLE | UCTD | MCTD: n (%) | 11 (85) | 1(8) | 1(8) |
| Females: n (%) | 7 (54) |
| Age at UCTD/MCTD/SLE onset (years): median (IQR) | 30 (25–34) |
| Age at myocarditis onset (years): median (IQR) | 37 (30–40) |
| Disease duration (years): median (IQR) | 17 (4–22) |
| General clinical features: n (%) | |
| Joint manifestations | 9 (82) |
| Mucocutaneous manifestations | 8 (64) |
| Haematological manifestations | 8 (64) |
| Lupus nephritis | 5 (36) |
| Neuropsychiatric SLE | 3 (18) |
| Serositis | 6 (45) |
| Constitutional symptoms | 4 (27) |
| Positive ADNA | 8 (64) |
| Positive antiphospholipid antibodies | 6 (45) |
| Treatment features | |
| Prednisone (any dose): n (%) | 2 (15) |
| Immunosuppressants: n (%) | 7 (54) |
| Mycophenolate mofetil | 6 (46) |
| Azathioprine | 1 (8) |
| Immunomodulants: n (%) | 8 (62) |
| Hydroxychloroquine | 7 (54) |
| Belimumab | 3 (23) |